International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(22), P. 16484 - 16484
Published: Nov. 18, 2023
Hepatocellular
carcinoma
(HCC)
is
a
highly
fatal
malignancy
with
limited
therapeutic
options
and
high
recurrence
rates.
Recently,
immunotherapeutic
agents
such
as
immune
checkpoint
inhibitors
(ICIs)
have
emerged
new
paradigm
shift
in
oncology.
ICIs,
programmed
cell
death
protein
1
(PD-1)
inhibitors,
provided
source
of
hope
for
patients
advanced
HCC.
Yet,
the
eligibility
criteria
HCC
ICIs
are
still
missing
piece
puzzle.
Circular
RNAs
(circRNAs)
recently
class
non-coding
that
play
fundamental
role
cancer
pathogenesis.
Structurally,
circRNAs
resistant
to
exonucleolytic
degradation
longer
half-life
than
their
linear
counterparts.
Functionally,
possess
capability
influence
various
facets
tumor
microenvironment,
especially
at
tumor–immune
synapse.
Notably,
been
observed
control
expression
molecules
within
cells,
potentially
impeding
effectiveness
ICIs.
Therefore,
this
renders
them
potential
cancer-immune
biomarkers
diagnosis,
prognosis,
regimen
determinants.
In
review,
authors
shed
light
on
structure
functional
roles
and,
most
importantly,
highlight
promising
immunomodulation
Advanced Science,
Journal Year:
2022,
Volume and Issue:
9(35)
Published: Oct. 26, 2022
Oxaliplatin
is
commonly
used
in
chemotherapeutic
regimens
for
colorectal
cancer
(CRC)
after
surgical
resection.
However,
acquired
chemoresistance
seriously
affects
the
curative
effect
CRC
patients,
and
mechanism
still
unclear.
Here,
a
circular
RNA,
circATG4B
identified,
which
plays
an
important
role
oxaliplatin
resistance
CRC.
expression
found
to
be
increased
exosomes
secreted
by
oxaliplatin-resistant
cells.
In
addition,
results
suggest
that
induces
promoting
autophagy.
Further
vivo
vitro
studies
indicate
of
attributed
its
potential
encode
novel
protein,
circATG4B-222aa.
Next,
circATG4B-222aa
function
as
decoy
competitively
interact
with
TMED10
prevent
from
binding
ATG4B,
leads
autophagy
followed
induction
chemoresistance.
Therefore,
this
study
reveals
exosomal
participates
decreased
chemosensitivity
cells,
providing
new
rationale
therapeutic
target
Cell Death and Disease,
Journal Year:
2023,
Volume and Issue:
14(6)
Published: June 9, 2023
Abstract
Globally,
colorectal
cancer
(CRC)
is
the
third
most
prevalent
and
second
leading
cause
of
cancer-related
deaths.
Circular
RNAs
(circRNAs)
are
single-stranded
RNA
with
covalently
closed-loop
structures
highly
stable,
conserved,
abundantly
expressed
in
various
organs
tissues.
Recent
research
found
abnormal
circRNA
expression
CRC
patients’
blood/serum,
cells,
tissues,
exosomes.
Furthermore,
mounting
data
demonstrated
that
circRNAs
crucial
to
development
CRC.
CircRNAs
have
been
shown
exert
biological
functions
by
acting
as
microRNA
sponges,
RNA-binding
protein
regulators
gene
splicing
transcription,
protein/peptide
translators.
These
characteristics
make
potential
markers
for
diagnosis
prognosis,
therapeutic
targets,
circRNA-based
therapies.
However,
further
studies
still
necessary
improve
understanding
roles
mechanisms
In
this
review,
up-to-date
on
role
was
examined,
focusing
their
application
targeted
therapy,
which
would
advance
knowledge
progression
Cell Death and Disease,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Jan. 4, 2024
Abstract
Current
treatment
strategies
for
cancer,
especially
advanced
are
limited
and
unsatisfactory.
One
of
the
most
substantial
advances
in
cancer
therapy,
last
decades,
was
discovery
a
new
layer
immunotherapy
approach,
immune
checkpoint
inhibitors
(ICIs),
which
can
specifically
activate
cells
by
targeting
checkpoints.
Immune
checkpoints
type
immunosuppressive
molecules
expressed
on
cells,
regulate
degree
activation
avoid
autoimmune
responses.
ICIs,
such
as
anti-PD-1/PD-L1
drugs,
has
shown
inspiring
efficacy
broad
applicability
across
various
cancers.
Unfortunately,
not
all
patients
benefit
remarkably
from
overall
response
rates
to
ICIs
remain
relatively
low
types.
Moreover,
primary
acquired
resistance
pose
serious
challenges
clinical
application
immunotherapy.
Thus,
deeper
understanding
molecular
biological
properties
regulatory
mechanisms
is
urgently
needed
improve
options
fo
r
current
therapies.
Recently,
circular
RNAs
(circRNAs)
have
attracted
increasing
attention,
only
due
their
involvement
aspects
hallmarks,
but
also
impact
shaping
tumor
microenvironment.
In
this
review,
we
systematically
summarize
status
existing
roles
circRNAs
Meanwhile,
aim
settle
issue
an
evidence-oriented
manner
that
involved
hallmarks
effects
Journal of Cellular Physiology,
Journal Year:
2023,
Volume and Issue:
238(9), P. 1982 - 2009
Published: July 14, 2023
Abstract
Being
a
leading
lethal
malignancy
worldwide,
the
pathophysiology
of
hepatocellular
carcinoma
(HCC)
has
gained
lot
interest.
Yet,
underlying
mechanistic
basis
liver
tumorigenesis
is
poorly
understood.
The
role
some
coding
genes
and
their
respective
translated
proteins,
then
later
on,
noncoding
RNAs
(ncRNAs)
such
as
microRNAs
have
been
extensively
studied
in
context
HCC
pathophysiology;
however,
implication
long
(lncRNAs)
circular
(circRNAs)
indeed
less
investigated.
As
subclass
ncRNAs
which
elusive
for
time
ago,
lncRNAs
was
found
to
be
involved
plentiful
cellular
functions
DNA,
RNA,
proteins
regulation.
Hence,
it
undisputed
that
dysregulation
profoundly
contributes
via
diverse
etiologies.
Accordingly,
represent
hot
research
topic
requires
prime
focus
HCC.
In
this
review,
authors
discuss
breakthrough
discoveries
involving
circRNAs
contributed
contemporary
concepts
how
these
could
leveraged
potential
novel
diagnostic
prognostic
biomarkers.
Further,
review
article
sheds
light
on
future
trends,
thereby
discussing
pathological
roles
proliferation,
migration,
epithelial‐to‐mesenchymal
transition.
Along
line
reasoning,
recommendations
targets
exploited
achieve
effective
HCC‐related
drug
development
highlighted.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(22), P. 16484 - 16484
Published: Nov. 18, 2023
Hepatocellular
carcinoma
(HCC)
is
a
highly
fatal
malignancy
with
limited
therapeutic
options
and
high
recurrence
rates.
Recently,
immunotherapeutic
agents
such
as
immune
checkpoint
inhibitors
(ICIs)
have
emerged
new
paradigm
shift
in
oncology.
ICIs,
programmed
cell
death
protein
1
(PD-1)
inhibitors,
provided
source
of
hope
for
patients
advanced
HCC.
Yet,
the
eligibility
criteria
HCC
ICIs
are
still
missing
piece
puzzle.
Circular
RNAs
(circRNAs)
recently
class
non-coding
that
play
fundamental
role
cancer
pathogenesis.
Structurally,
circRNAs
resistant
to
exonucleolytic
degradation
longer
half-life
than
their
linear
counterparts.
Functionally,
possess
capability
influence
various
facets
tumor
microenvironment,
especially
at
tumor–immune
synapse.
Notably,
been
observed
control
expression
molecules
within
cells,
potentially
impeding
effectiveness
ICIs.
Therefore,
this
renders
them
potential
cancer-immune
biomarkers
diagnosis,
prognosis,
regimen
determinants.
In
review,
authors
shed
light
on
structure
functional
roles
and,
most
importantly,
highlight
promising
immunomodulation
